Answers are grounded in this paper and cite their sources.
Major depressive disorder (MDD) is a leading cause of disability, yet current antidepressants are limited by treatment resistance and delayed onset. Neuroimmune inflammation and aberrant synaptic pruning are core pathological drivers, but targeted therapeutics remain scarce. Hydroxycarboxylic acid receptor 2 (HCAR2), a microglia-enriched GPCR and the target of niacin, has shown anti-inflammatory potential, but its role in depression is unknown. Using a chronic unpredictable mild stress mouse model with bidirectional HCAR2 manipulation, we found that chronic stress impaired hippocampal HCAR2 signaling. Niacin robustly alleviated depressive-like behaviors, whereas HCAR2 knockout markedly attenuated these effects and exacerbated stress vulnerability. Mechanistically, HCAR2 activation suppressed hippocampal neuroinflammation and microglial NLRP3 inflammasome activation via a non-canonical, ARRB2-dependent endocytic pathway: activated HCAR2 internalized into microglial endosomes, bound NEK7, and blocked NLRP3 inflammasome assembly. Concurrently, HCAR2 preserved synaptic integrity by inhibiting complement C3/CR3 signaling and attenuating excessive microglial synaptic phagocytosis. In conclusion, HCAR2 acts as an endogenous protective regulator in depression via dual mechanisms: ARRB2-mediated endosomal sequestration of NEK7 to suppress NLRP3 inflammasome, and inhibition of complement-driven synaptic pruning. These findings identify HCAR2 as a promising therapeutic target and provide a rationale for repurposing niacin in MDD treatment.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: